Federal Judge Rules Against Liquidia in Pulmonary Hypertension Patent Dispute
In a significant development for the pharmaceutical industry, a Delaware federal judge has determined that Liquidia Technologies infringed upon a patent that protects methods for treating pulmonary hypertension associated with interstitial lung disease. This conclusion stems from Liquidia’s attempts to secure approval for Yutrepia, a drug designed to address this medical condition. The ruling reinforces…